Haemonetics Corp (HAE) 37.80 $HAE
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on Monday, September 12, 2016 at 1:40pm Eastern time.
HAE: 37.80 (+0.48), MS: 31.89 (-0.02)
Haemonetics to Present at The Baird 2016 Global Healthcare Conference
PR Newswire - Mon Aug 29, 3:15PM CDT
Haemonetics Corporation (NYSE:HAE) announced that Gerry Gould, Vice President - Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time.
HAE: 37.80 (+0.48)
Shares of HAE Up 23.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 26, 1:41PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 23.17% as of today's recent price of $36.07.
HAE: 37.80 (+0.48)
Haemonetics Shares Up 21.9% Since SmarTrend's Buy Recommendation (HAE)
Comtex SmarTrend(R) - Fri Aug 19, 1:19AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 21.94% as of today's recent price of $35.71.
HAE: 37.80 (+0.48)
Downgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue Aug 16, 3:06AM CDT
Haemonetics (NYSE:HAE) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $35.75 on volume of 416,000 shares, above average daily volume of 408,000. Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections. Haemonetics markets its products worldwide, primarily outside the United States.
HAE: 37.80 (+0.48)
Uptrend Call Working As Haemonetics Stock Rises 22.9% (HAE)
Comtex SmarTrend(R) - Thu Aug 11, 1:12AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 22.93% as of today's recent price of $36.00.
HAE: 37.80 (+0.48)
Haemonetics CEO Completes Open Market Share Purchase
PR Newswire - Mon Aug 08, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.
HAE: 37.80 (+0.48)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), HAE: 37.80 (+0.48), CPHD: 34.42 (+0.16)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 37.80 (+0.48), NUVA: 66.74 (+0.68)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 37.80 (+0.48)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 37.80 (+0.48)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), HAE: 37.80 (+0.48), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 37.80 (+0.48)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 37.80 (+0.48)
Upgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue May 17, 3:13AM CDT
Haemonetics (NYSE:HAE) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $27.73 on volume of 586,000 shares, above average daily volume of 408,000. In the past 52 weeks, shares of Haemonetics have traded between a low of $25.98 and a high of $43.85 and closed yesterday at $27.73, which is 7% above that low price. The 200-day and 50-day moving averages have moved 0.68% lower and 0.96% lower over the past week, respectively.
HAE: 37.80 (+0.48)
Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer
PR Newswire - Mon May 09, 4:00PM CDT
Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
HAE: 37.80 (+0.48)
Why Baidu, Pandora Media, and Haemonetics Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 02, 4:45PM CDT
Monday was a positive day on Wall Street, and the stock market bounced back from losses to close last week. The Dow picked up a triple-digit daily gain, and most broad-based market benchmarks rose between 0.75% and 1% on the day. Somewhat...
BIDU: 177.78 (+1.23), P: 14.43 (+0.05), HAE: 37.80 (+0.48)
Haemonetics reports 4Q loss
Automated Insights - Mon May 02, 5:31AM CDT
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported a loss of $8.8 million in its fiscal fourth quarter.
HAE: 37.80 (+0.48)
Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported
PR Newswire - Mon May 02, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%. Revenue was up 10% over the fourth quarter of fiscal 2015 in constant currency, benefiting by 6.8% from the inclusion of a 53rd week.
HAE: 37.80 (+0.48)
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on Monday, September 12, 2016 at 1:40pm Eastern time.
HAE: 37.80 (+0.48), MS: 31.89 (-0.02)
Haemonetics to Present at The Baird 2016 Global Healthcare Conference
PR Newswire - Mon Aug 29, 3:15PM CDT
Haemonetics Corporation (NYSE:HAE) announced that Gerry Gould, Vice President - Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time.
HAE: 37.80 (+0.48)
Shares of HAE Up 23.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 26, 1:41PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 23.17% as of today's recent price of $36.07.
HAE: 37.80 (+0.48)
Haemonetics Shares Up 21.9% Since SmarTrend's Buy Recommendation (HAE)
Comtex SmarTrend(R) - Fri Aug 19, 1:19AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 21.94% as of today's recent price of $35.71.
HAE: 37.80 (+0.48)
Downgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue Aug 16, 3:06AM CDT
Haemonetics (NYSE:HAE) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $35.75 on volume of 416,000 shares, above average daily volume of 408,000. Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections. Haemonetics markets its products worldwide, primarily outside the United States.
HAE: 37.80 (+0.48)
Uptrend Call Working As Haemonetics Stock Rises 22.9% (HAE)
Comtex SmarTrend(R) - Thu Aug 11, 1:12AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 22.93% as of today's recent price of $36.00.
HAE: 37.80 (+0.48)
Haemonetics CEO Completes Open Market Share Purchase
PR Newswire - Mon Aug 08, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.
HAE: 37.80 (+0.48)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), HAE: 37.80 (+0.48), CPHD: 34.42 (+0.16)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 37.80 (+0.48), NUVA: 66.74 (+0.68)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 37.80 (+0.48)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 37.80 (+0.48)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), HAE: 37.80 (+0.48), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 37.80 (+0.48)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 37.80 (+0.48)
Upgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue May 17, 3:13AM CDT
Haemonetics (NYSE:HAE) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $27.73 on volume of 586,000 shares, above average daily volume of 408,000. In the past 52 weeks, shares of Haemonetics have traded between a low of $25.98 and a high of $43.85 and closed yesterday at $27.73, which is 7% above that low price. The 200-day and 50-day moving averages have moved 0.68% lower and 0.96% lower over the past week, respectively.
HAE: 37.80 (+0.48)
Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer
PR Newswire - Mon May 09, 4:00PM CDT
Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
HAE: 37.80 (+0.48)
Why Baidu, Pandora Media, and Haemonetics Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 02, 4:45PM CDT
Monday was a positive day on Wall Street, and the stock market bounced back from losses to close last week. The Dow picked up a triple-digit daily gain, and most broad-based market benchmarks rose between 0.75% and 1% on the day. Somewhat...
BIDU: 177.78 (+1.23), P: 14.43 (+0.05), HAE: 37.80 (+0.48)
Haemonetics reports 4Q loss
Automated Insights - Mon May 02, 5:31AM CDT
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported a loss of $8.8 million in its fiscal fourth quarter.
HAE: 37.80 (+0.48)
Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported
PR Newswire - Mon May 02, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%. Revenue was up 10% over the fourth quarter of fiscal 2015 in constant currency, benefiting by 6.8% from the inclusion of a 53rd week.
HAE: 37.80 (+0.48)
